The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

Cladribine is a purine nucleoside analog initially developed in the 1970s as a treatment for various blood cancers. Due to the molecule’s ability to preferentially reduce T and B lymphocytes, it has been developed into an oral formulation for the treatment of multiple sclerosis (MS). The unique prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Rammohan, Kottil, Coyle, Patricia K., Sylvester, Elke, Galazka, Andrew, Dangond, Fernando, Grosso, Megan, Leist, Thomas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708385/
https://www.ncbi.nlm.nih.gov/pubmed/33247831
http://dx.doi.org/10.1007/s40265-020-01422-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708385/
https://www.ncbi.nlm.nih.gov/pubmed/33247831
http://dx.doi.org/10.1007/s40265-020-01422-9

Ejemplares similares